Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.

摘要: BACKGROUND The superiority of new generation aromatase inhibitors over tamoxifen in the adjuvant treatment early breast carcinoma has emerged from several randomized trials. However, until now not all previous studies have shown a mortality benefit. METHODS A pooled analysis 2 prospective multicentric trials, sharing same study design and nearly identical inclusion criteria, was performed. In both women treated previously with for or 3 years were randomly assigned to either continuing an additional having their switched aminoglutethimide anastrozole comparable time period. Mortality analyzed according allocated other patient tumor variables. RESULTS In all, 828 postmenopausal women, mostly estrogen receptor (ER)-positive node-positive tumors who had been monitored median 78 months (range, 6–141 months) analyzed. Of these 415 selected continue 413 anastrozole. All-cause cancer-specific significantly improved by switch: all-cause mortality: hazard ratio (HR) = 0.61 (0.42–0.88) P .007; HR (0.39–0.94) .025. No increase recorded cancer-unrelated after switching. Multivariate showed that age, size, treatment, nodal status, order, independent predictors. CONCLUSIONS Switching inhibitor therapy improves survival compared treatment. Cancer 2007. © 2007 American Society.